GE Healthcare OncoQuant Brochure
Robust tools for routine Oncology
diagnosis, treatment follow-up,
reporting and clinical trial management.
GE Healthcare
Oncology follow-up exams make up over 70% of routine studies.
Due to the expanding breadth of data associated with today’s
multi-modality, multiple time-point Oncology studies, reviewing
these exams can be time-consuming and labor-intensive. AW’s
Oncoquant application is designed to help organize and display
your Oncology data to facilitate your quick review. Oncoquant
provides innovative analysis and reporting tools aimed at
improving both your clinical capabilities and your reading
workflow.
Automatic multi-modality
image registration at loading
for two or more exams.1
Adaptable workflow supports
standard criteria such as
RECIST 1.0, 1.1,
2
WHO.
3
Dedicated automatic review
protocols to identify and load
like series.
Right-click menu workflow
measurements at baseline and
follow-up.
Intuitive, interactive Summary
Table.
Single-click Quick Report
displays up to four dates
including Baseline, Nadir, Prior,
and Current exams.
OncoQuant
Visit us:
www.gehealthcare.com/aw/
applications/oncoquant/
Overview
OncoQuant medical diagnostic software
streamlines Oncology reading so you can
spend less time retrieving studies and preparing
exams, and more time reading and reviewing. A
true cross-modality Oncology reading platform,
OncoQuant helps you correlate and compare
CT, MR, PET/CT, and 3D X-ray data. It automates
workflow to facilitate comparisons over time
and makes reviewing follow-up exams more
efficient. The Oncology Review protocol and
follow-up wizard simplify the assessment,
characterization and measurement of findings
on the basis of morphologic criteria.
Features
Automatic Registration/
Synchronization1.
Intelligent review, comparison, and
follow up with dedicated protocols.
Manages cases between several
modalities with no upper limit on
the number of exams.
Advanced Visualization tools:
‐ Autocontour tool provides
consistent contouring.
‐ Lung VCAR algorithm for lung
nodules in CT.4
‐ The Volume Viewer Arrow tool
lets you mark any finding as an
area of interest.
Summary table:
‐ Baseline and follow up
management
‐ Drag and drop Follow up wizard.
‐ Target type selection
‐ Research tools
Saves and reloads image and
measurements of prior Oncology
exams.
Exports DICOM and non DICOM
images of findings, measurements.
Quick report of the entire summary
table includes up to 4 exam dates.
Statistical results export in CSV
format for Excel or OpenOffice.
Regulatory Compliance
This product complies with the
European Council Directive
93/42/EEC Medical Device Directive
as amended by European Council
Directive 2007/47/EC.
References
1
Integrated Registration Multi-Modality
option required.
2
RECIST is a guideline to perform clinical
trials. Rules and guidelines can be found on
the official website
http://www.eortc.be/Recist/Default.htm
3
See WHO criteria in the publication:
Measures of Response: RECIST, WHO, and
New Alternatives, J Clin Oncol 24:3245-3251.
4
Lung VCAR option required.
System Requirements
Minimum platform release:
AW VolumeShare 5 Enhanced or
AW Server 2.
Pre-requisite software:
Volume Viewer Enhanced is
required for VV General Review.
Integrated Registration is required
for Automatic
Registration/Synchronization.
Lung VCAR is required for nodule
segmentation and measurements.
Indications for Use
OncoQuant is medical diagnostic
software that allows the processing,
review, analysis and communication
of 3D reconstructed images and their
relationship to originally acquired
images from CT, MR, X-Ray
Angiography, SPECT, and PET
scanning devices. The combination of
acquired images, reconstructed
images, annotations, and
measurements performed by the
clinician are intended to provide to
the referring physician clinically
relevant information for diagnosis,
surgery and treatment planning, and
follow-up.
© 2012 General Electric Company.
All rights reserved. Data subject to change.
GE and GE Monogram are trademarks of General Electric Company.
* Trademark of General Electric Company.
Loading...